TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06775600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Replacement
Description: Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Replacement
Description: Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Replacement
Description: Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.
Study: NCT06771752

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire will be made comprised of the questions taken from the Whole Day Matters Toolkit (WDMT) 24-hour movement questionnaire (The Canadian Society for Exercise Physiology, 2021), which is based on the official 24-hour movement guidelines (Ross et al., 2020) (see appendix). For diet quality, Mini-EAT, a short dietary screening tool will be used (Lara-Breitinger et al., 2023) (see appendix). The questionnaire will be open for two months during the football mid-season time period (January 15th to March 15th). The principal investigator will distribute the questionnaire digitally via Google Forms. It will be sent directly to sports staff professionals, individually and to football clubs and to universities to distribute to their cohort. Only people with the link will be able to access the questionnaire. Participants will answer the questionnaire, which will take roughly 10 minutes, completing the intervention.
Study: NCT06775678

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy
Description: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fractionated radiotherapy
Description: Conventional fractionated radiotherapy
Study: NCT06776211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation
Description: Virtual reality simulation application:~The video content to be used in the virtual reality-based application was created by researchers from the Ministry of Health of the Republic of Turkey, General Directorate of Public Health, Neonatal Resuscitation Programme (NRP) Practitioner Certified Training Programme. The duration of the video was planned not to exceed 10 minutes in order not to reduce the interest and attention span.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Reality Simulation
Description: Low reality simulation application: The low reality simulation application to be used will use a neonatal model as a teaching aid, with human anatomy and functional features designed to simulate neonatal resuscitation applications.
Study: NCT06776445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline combined with hydroxychloroquine
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin 300mg bid
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin 300mg tid
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
Study: NCT06776783

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)
Description: Subjects in the AeroFact group will be changed from their current nCPAP/NIV interface to the AeroFact nCPAP/NIV interface and AeroFact treatment will be started.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control/Sham
Description: Subjects in the Control group will continue nCPAP/NIV and will not receive any placebo or AeroFact. The Sham treatment of Control subjects will consist of placing an AeroFact Controller at the bedside but will not include replacing their nCPAP/NIV interface with the AeroFact nCPAP/NIV interface. A respiration sensor will also be placed on the abdomen to detect and display respiratory pattern on the Controller display screen.
Study: NCT05750017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Recombinant Herpes Zoster Vaccine (LZ901)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
Study: NCT03848260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic device prototype
Description: The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
Study: NCT06385652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NB381
Description: Lei Kang from Peking University First Hospital and Bing Jia's team from the School of Basic Medical Sciences at Peking University have developed a targeted CD38 nanobody sequence using genetic engineering technology. They have optimized its structure, functionalized it with labeling, and conducted imaging and other evaluations, ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381. The post-labeling quality control of the drug meets clinical trial requirements with a radiochemical purity (PCR) greater than 98% and in vitro stability not less than 90%.~Preliminary PET imaging results of 68Ga-NB381 indicate that the nanobody is primarily concentrated in the kidneys, bladder, and MM.1S and Ramos or H929 tumors (CD38+). Additionally, the cold antibody NB381 significantly inhibits the uptake of 68Ga-NB381 in tumors, confirming the high specificity of this nanobody's binding to the CD38 protein.
Study: NCT06772987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated rTMS treatment
Description: 1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.
Study: NCT06777446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective Adhesionlysis
Description: See descriptions in study arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesion barrier
Description: At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).
Study: NCT06777095

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment + I Taping
Description: Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, I taping (a total of 5 times every 3 days) was performed. Two I-shaped kinesio tapings were applied on the paraspinal muscles from the posterior superior iliac spine to the T12 level. 50% tension was applied to the area of the tapes outside the anchor points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment + Star Taping
Description: Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, star taping (a total of 5 times every 3 days) was performed. Four I tapes, one vertical, one horizontal and two at a 45° angle to the vertical tape, were applied to the point of maximum pain in the lumbar region. 25% tension was applied to the midpoint of the tapes except for the ends.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Treatment
Description: Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. No taping was applied.
Study: NCT06776055

Intervention type: BIOLOGICAL
Intervention: HPV-16/18 vaccine
Description: Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)
Study: NCT06119620

Intervention type: DEVICE
Group type: OTHER
Intervention: intermitted theta burst stimulation
Description: Participants receive intermitted theta burst stimulation for 3-4 minutes before completing the N-back task.
Study: NCT04940273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Injection [Ultiva]
Description: Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
Study: NCT05917457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance coordination and strengthening training
Description: The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group.~Study group: Low vision children were given balance, coordination training and general strengthening training with sandbags for 70 minutes 3 days a week (5-minute warm-up phase, 20-minute balance training, 20-minute coordination training, 20-minute strengthening training and 5-minute cooling phase) for 8 weeks.
Study: NCT05754892

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
Study: NCT06776055

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.
Study: NCT05754892

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor sample
Description: For patients with ACC and patients with MPP : tumor sample during surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor sample
Description: For patients with ACC and patients with MPP : tumor sample during surgery
Study: NCT05872204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablet once daily
Study: NCT06300203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-4 receptor responders
Description: Interleukin-4 receptor was injected subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was injected subcutaneously.
Study: NCT06352112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: PFMT consisted of both slow voluntary contractions lasting 15 seconds each (5-s contraction, 5-s hold and 5-s relaxation) and fast voluntary contractions lasting 2-s each. A set of exercises included 10 slow and 10 fast voluntary contractions. During the first week, women performed five sets of exercises a day, and the exercises were continued for eight weeks by increasing five sets each week. The exercises were performed as home exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: PFMT consisted of both slow voluntary contractions lasting 15 seconds each (5-s contraction, 5-s hold and 5-s relaxation) and fast voluntary contractions lasting 2-s each. A set of exercises included 10 slow and 10 fast voluntary contractions. During the first week, women performed five sets of exercises a day, and the exercises were continued for eight weeks by increasing five sets each week. The exercises were performed as home exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive Exercises
Description: HE program in which different placements of the upper and lower extremities were used in standing, sitting and supine positions, and the participants were asked to perform the exercises with a hypopressive maneuver to maintain apnea and rib cage expansion for approximately 10 seconds. Exercises were started with three repetitions a day, and then the number of repetitions was increased to five and/or 10, depending on the participant's tolerance. The exercises were performed as home exercises.
Study: NCT05644054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
Study: NCT05060276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3258
Description: Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
Study: NCT06771778

Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: A Qualtrics link was provided for current and former NICU RDNs to complete a 10-minute online survey that provided an optional gift card for completion. Part 1 of the survey had eight questions, and part 2 had eleven additional questions.
Study: NCT05976997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib, Chidamide
Description: Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
Study: NCT06776458

Intervention type: OTHER
Intervention: N/A - Usual Care
Description: Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.

Intervention type: OTHER
Intervention: N/A - Usual Care
Description: Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
Study: NCT05501821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBA1412
Description: Part A, B, C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBA1412
Description: Part A, B, C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBA1412
Description: Part A, B, C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Part C only
Study: NCT05915663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasogastric tube and orogastric tube
Description: nasogastric tube in period 1 and orogastric tube in period 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orogastric tube and nasogastric tube
Description: orogastric tube in period 1 and nasogastric tube in period 2
Study: NCT06776458

Intervention type: OTHER
Intervention: N/A - Usual Care
Description: Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
Study: NCT06776718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES
Description: vNOTES for benign hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal hysterectomy
Description: vaginal hysterectomy for benign hysterectomy
Study: NCT06775834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893
Description: HRS-1893 tablets.
Study: NCT05548933

Intervention type: PROCEDURE
Intervention: non-surgical periodontal therapy
Description: supragingival scaling,subgingival scaling

Intervention type: PROCEDURE
Intervention: non-surgical periodontal therapy
Description: supragingival scaling,subgingival scaling
Study: NCT05402189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketodex, Fentanyl
Description: The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketodex, Fentanyl
Description: The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.
Study: NCT03977064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style change and weight reduction
Description: Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
Study: NCT04850417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
Study: NCT05872269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar
Description: 4 Mg Oral Tablet
Study: NCT04723446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate
Description: Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Peroxyl® -1.5% Hydrogen peroxide
Description: Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride
Description: The Oral-B® Gum \& Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
Study: NCT06775821

Intervention type: DEVICE
Intervention: Ultrasound or CT of the abdominal aorta
Description: Patient underwent ultrasound or CT of the abdominal aorta